Bibliographie
[1] AKINHBEHIN T. , VILLAD JR.
Metipranolol-associated granulomatous anterior uveitis.
Br J Ophlhalmol., 1991 ; 75 : 519- 524.
[2] ALM A., VILLUMSEN J.
PhXA34, a new potent ocular hypotensive drug. A study on
dose-response relationship and on aqueous humor dynâmics in healthy
volunteers.
Arc Ophthalmol., 1991 ; 109 : 1564-1568.
[3] ALM A., STJERNCHANTZ J.
Effects on intraocular pressure and side effects of 0.005 %
Latanoprost applied once daily. evening or mornlng. Acomparison with timolol.
Ophthalmology, 1995 ; 102 : 1743-1752.
[4] ALWARD WL.
The requisites in ophthalmology.
Dans Krachmer, J.S. (éd.), Glaucoma. Mosby, St-Louis
(2000) : 10-14.
[5] AUIDUGE A., AUZEMERY A., CESSON JF., DUCOUSSO
F.
La stratégie de lutte contre le glaucome.
Cahiers santé, 1998 ; 8 : 157-158.
[6] BÉCHETOILLE A.
Glaucomes primitifs par fermeture de l'angle.
EMC (Paris-France) ; 21280A10 ; 1989 ; 4 : 16.
[7] BECHETOILLE.A
Les glaucomes.
2 édition Jappenard, 1997 ; 1 : 7.
[8] BECHETOILLE A., BRON A.
Les bonnes pratiques thérapeutiques de glaucome chronique
à angle ouvert.
Journal français d'ophtalmologie, 2000 ;
23 : 272-277.
[9] BERSON FG., COHEN HB., FOERSTER RJ., LASS JH.,
Levobunolol compared with timolol for the long, term control of
elevated Intraocular pressure.
Arch Ophthalmol., 1985 ; 103 : 379-382.
[10] BRON A., LIPPA EA., GUNNING F.
Multiple dose efficacy comparison of the two topical carbonic
anhydrase inhibitors sezolamide and MK-927.
Arch Ophthalmol., 1991 ; 109 : 50-53.
[11] BRON A.
Traitement des glaucomes.
La revue du praticien, 2001, 51 : 2198-2201.
[12] BROWN FG., FLETCHER R.
Historical background and evolution of primary health care.
Modern Optometry. Glaucoma in Optometric Practice. Oxford :
Blackwell Scientific Publications, 1990 : 1-17.
[13] CAMRAS CB., PODOS SM.
The role of endogenous prostaglandins in clinically-used and
investigational glaucoma therapy. In: Bito LZ, Sternschantz J eds. The ocular
effects of prostaglandins and other eicosanoids.
New York: Alan R Liss, 1989.
[14] CAMRAS CB.
The Brinzolamide Primary Therapy Study Group. A triple-masked,
primary therapy study off the efficacy and safety of BID and TID-dosed
brinzolamide 1 % compared TID-dorzalamide 2 % and BID-dosed timolol 0.5 %.
Invest Ophthalmol Vis Sci., 1997 ; 38 : S560.
[15] CEPELIC J., CERMOHORSKY M.
The effects of adrenergic agonists on the adenylate cyclase in
albino rabbit ciliary processes.
Exp Eye Res., 1981 ; 32 : 291-299.
[16] CHANDLER ML., DE SANTIS L.
Studies of p-aminoclonidine as a potential antiglaucoma agent.
Invest Ophthalmol Vis Sci., 1985 ; 25 (suppl) : S227.
[17] CHEVALERAUD J.P.
L'examen du champ visuel.
EMC (Paris, France) ; 1986 ; 6 : 18.
[18] COAKES RL., BRUBAKER RS.
The mechanism 01 timolol in lowering intraocular pressure.
Arch Ophthalmol., 1981 ; 96 : 2045-2048.
[19] COLLIGNON, BRACH J.
Le glaucome par fermeture de l'angle.
J Fr Ophtalmol., 1984 ; 7 : 333-346.
[20] DANYLUK AW., PATON D.
Diagnosis and Management of Glaucoma.
Clinical Symposia (CIBA-GEIGY), 1992 ; 43: 3- 4.
[21] DENIS P.
Contribution à l'étude de la régulation
neuropharmacologique de la pression intra-oculaire.
Thèse, Paris, 1990.
[22] ENCARTA 2005
Encyclopédie ; Collection Microsoft ® Encarta
2005.
[23] ETIENNE R.
Le glaucome primitif à angle ouvert, comité de
lutte contre le glaucome
Simep, Ed. Villeurbanne; 1982 : 219.
[24] ETIENNE R.
Traitement médical et chirurgical des glaucomes.
Marseille: Diffusion générale de librairie ;
1987 : 1-329.
[25] FEITI ME., KRUPIN T.
Hyperosmotic agents. ln: Rich R. Shietds MB Krupin T
Eds. The glaucomas. St Louis: CV Mosby, 1989 : 551-555.
[26] FLAMENT J.
Ophtalmologie Pathologie du système visuel.
MASSON, 2002 : 219-247.
[27] FREEDMAN SF.; SHIEDS MB.; LOBAUGH B., SAMSA
GP.
Effects of ocular carteolol and timolol on plasma high-density
Iipoprotein cholesterol level.
Am J Ophthalmol, 1993 ; 116 : 600-604.
[28] GHARAGOZIOO NZ., LARSON NS., KULLERSTAND
W.
Terbutaline stimulates aqueous humor flow in humans during
sleep.
Arch Ophtalmol, 1989 ; 49 : 389-402.
[29] GLAUCOMA LASER TRIAL RESEARCH GROUP.
The Glaucoma Laser Trial (GLT). IV. Contralateral effects of
timolof on the intraocular pressure 0f eyes treated with ALT.
Opthalmic. Surg., 1991 ; 22: 234-240.
[30] HAMARD H.
Décision en ophtalmologie.
Editions VIGOT, 1993 : 78-91.
[31] HARRIS LS., GREENSTEIN SH., BLOOM AF.
Respiratory difficulties with betaxolol.
Am J Ophthalmol., 1986 ; 102 : 274-275.
[32] HENKIND P., PRIEST RS., SCHILLER G.
Glossary of clinical terms.
G. Compendium of Ophthalmology. Philadelphia: J.B. Lippincott
Company, 1983 : 122-124.
[33] HODAPP E., KOLKER A., KASS MA., GOLDBERG L., BECKER
B.
The effect of topical clonidine on intraocular pressure.
Arch Ophthalmol., 1981 ; 99 : 1208-1211.
[34] HOSKINS H.D.; KASS M.A.
Carbonic anhydrase inhibitors. ln: Becker-Shaffer's diagnosis and
therapy of the glaucomas.
ST Louis: CV Mosby, 1989 : 470-484.
[35] JAMPEL H., McGUIGHAN L.
Biology of experimental glaucoma filtering surgery failure.
Invest Ophtalmol Vis Sci., 1987 ; 28 : 378.
[36] KAHN HA., MILTON RC.
Alternative definitions of open-angle glaucoma, effet on
prevalence and association in the Framingham eye study.
Arch Ophtalmol., 1980 ; 98 : 2172-2177.
[37] KAUFMAN PL.
Pressure-dependent ouflow. In: Ritch E, Shields MB, Krupin T.
Eds. The glaucomas. St-Louis: CV Mosby, 1989.
[38] KERR CL., HAAS J., DRANCE S., WALTERS M., SCHULTZER
M.
Cardiovascular effects of epinephrine and dipivalyl epinephrine
applied topically to the eye in patients with glaucoma.
Br J Ophthalmol., 1982 ; 66 : 109-112.
[39] KITAZAWA Y., AZUMA L., ARAIE M., SHIRATO S.
Topical dorzolamide hydrochloride can be a substitute for oral
carbonic anhydrase inhibitors.
Invest Optlhalmol Vis Sci., 1994 ; 35 : S2177.
[40] KLAPPER RM.
Q-swiched neodinium : YAG laser iridectomy.
Ophtalmology, 1984 ; 91 : 1017-1021.
[41] KOHN AN., MOSS A., HARGETT N., RITCH R., SMITH H.
Clinical comparison of dipivalyl epinephrine and epinephrine ln
the treatment 0f glaucoma.
Am J Ophthalmol., 1980 ; 87 : 196-201.
[42] KOLKER AE., HETHERINGTON JJr.
Becker-shaeffer's diagnosis and therapy of the glaucomas.
C.V. Mosby Co. Ed. St Louis, 1993 : 608.
[43] KOSKELA T., BRUBAKER RF.
Apraclonidine and timolol. Cambined effects in previously
untreated normal subjects.
Arch Ophtalmol., 1991 ; 109 : 1069-1074.
[44] LACHKAR Y., BERKANI M.
Le glaucome.
Concours médical, 2001 ; 123 : 27.
[45] LAIBOVITZ R., STRAHLMAN ER., BARBER BL.
Comparison of quality of life and patient preference of
dorzolamide and pilocarpine as adjunctive therapy to timoIoI in the treatment
of glaucoma.
J Glaucoma., 1995 ; 4 : 306-31.
[46] LAURENCE J. et al.
A double-masked placebo-controlled evaluation of timolol in a gel
vehicule.
J Glaucoma., 1993 ; 2 : 177-180.
[47] LE JEUNNE C., BRINGER L., MONDJEE TZ., MUNERA Y.
Cardiovascular effects of eye drops containing timolol,
carteolol, metipranolol and betaxolol in elderly subjects.
Thérapie ; 1989 ; 43 : 89-92.
[48] LI Y., SCHLAMP CL., NICKELLS RW.
Experimental induction of retinal ganglion cell death in adult
mice.
Invest Ophthalmol Vis Sci., 1999 ; 40 : 1004-1008.
[49] LINDSEY JD., WEINREB RN.
Induction of c-Fos by prostaglandin F2a in human ciliary smooth
muscle cells. Invest Ophthalmol Vis Sci., 1994 ; 35 : 242-245.
[50] LIPPA EA., CARSTON LE., EHINGER B.
Dose response and duration of action of dorzolamide. A topical
carbonic anhydrase inhibitor.
Arch Ophthalmol., 1992 ; 110: 495-499.
[51] MANDAVA S., SWEENEY T., GUYER D.
Atlas de poche en couleur d'ophtalmologie.
FLAMMARION, 2001 : 238.
[52] MANDELL AI., STENTZ F., KITABCHI AE.
Dipivalyl epinephrine : a new pro-drug in the treatment of
glaucoma. Ophthalmology, 1981 ; 85 : 268-273.
[53] MAUS TL., LARSSON L., McLAREN JW., BRUBAKER RF.
Comparison of dorzolamide and acetazolamide as suppressors of
aqueous humor flow in humans.
Arch Ophthalmol., 1997 ; 115 : 45-49.
[54] NEUFELD A.H.
Influences of cyclic nucleotides on outflow facility in the
vervet monkey.
Exp Eye Res., 1981 ; 27 : 387-397.
[55] NEWELL W.
The Glaucomas. Édité par Klein EA. Ophthalmology
principles and concepts fifth.
Edition St-Louis : The C.V. Mosby Company, 1982 : 340-341.
[56] NGUYEN KD., SHIN DH.
Prevalence of apraclonidine allergy and its relationship to
propine allergy.
Invest Ophlhalmol Vis Sci., 1996 ; 37 : S1103.
[57] NILSON SF.
Studies on ocular blood flow and aqueous humor dynamics. Effects
of VIP and PHI related to the effects of facial nerve stimulation.
Acta Univ Uppsala., 1986 ; 43 : 1-38.
[58] NORDLUND JR., PASQUALE LR., ROBIN AL.
The cardiovascular pulmonary and ocular hypotensive effects of
0.2 % brimonidine.
Arch Ophthalmol., 1995 ; 113 : 77-83.
[59] OSBORNE NN., UGARTE M., CHAO M.
Neuroprotection in relation to retinal ischemia and relevance to
glaucoma.
Surv Ophthalmol., 1999 ; 43 : S102-S128.
[60] PILLUNAT L.; STODTMEISTER R.
Ellect of different antiglaucoma tous drugs on ocular perfusion
pressures.
J Ocul Pharmacol., 1988 ; 4 : 231-242.
[61] PLEILLER N.
Dorzolamide : development and clinical application of a topical
carbonic anhydrase inhibitor.
Surv Ophthalmol., 1997 ; 42 : 137-151.
[62] QUIGLEY HA., SANCHEZ RM.
Chronic glaucoma selectivity damages large optic nerve fibers.
Invest Ophthalmol Vis Sci., 1987 ; 28 :
913-920.
[63] REGEVAND GS.
Le glaucome : le nouveau rôle du médecin
traitant dans la prise en charge du patient glaucomateux.
Médecine et hygiène, 1999 ; 57 :
81-82.
[64] REISS GR., LEED DA., TOPPER JE., BRUBAKER
RF.
Aqueous humor flow during sleep.
Invest Ophthalmol Vis Sci., 1984 ; 25 :
776-778.
[65] ROBIN AL., POLIACK IP., DELALLER JM.
Effects 01 topical ALO2145 on the acute intraocular pressure use
after argon laser iridectomy.
Arch Ophlhalmol., 1987 ; 105 : 1208-1211.
[66] ROBIN AL.; Ritch R., Shin DH., Smythe B., Mundorf
T.
Short-term efficacy of apraclonidine hydrochloride added to
maximum-toleraled therapy for glaucoma.
Am J Ophthalmol., 1995 ; 120 : 423-432.
[67] RODRIGUES MM., SPAETH GL.
Electron microscopy of aragon laser therapy in phakic open-angle
glaucoma.
Ophthalmology, 1989 : 198-210.
[68] ROMANET JP., NOEL C.
Humeur aqueuse et pression intraoculaire.
EMC (Elsevier,Paris), Ophtalmologie ; 1998 : 8.
[69] ROUGIER J. ; MAUGERY J.
Ophtalmologie pour le praticien.
SIMEP, 1989 ; 82 : 1-4.
[70] RUGEVAND GS.
Le glaucome : le nouveau rôle du médecin
traitant dans la prise en charge du patient glaucomateux.
Médecine et hygiène, 1999 ; 57 :
81-82.
[71] RULO AH., GREVE EL., HOYNG PF.
Additive effect of latanoprost and timolol in patients wilh
elavated intraocular pressure.
Br J Ophthalmol., 1994 ; 78 : 899-902.
[72] SARAUX H., BIAIS B., ROSSAZZA C.
Ophtalmologie.
MASSON, 2eme edition ; 1988 : 217-234.
[73] SELEM G., STJERNSCHANTZ J., RESUL B.
Prostaglandin-induced iridial pigmentation in primates.
Surv ophthalmol., 1997 ; 41 : S125-128.
[74] SELLEM E., COTTIER F., MAUGERY J.
Efficacité et tolérance de la dipivéphrine
dans le traitement de l'hypertension intraoculaire primitive.
Bull Soc Ophtalmol., 1987 ; 5 : 675-680.
[75] SELLEM E.
Glaucome primitif à angle ouvert.
-Editions techniques- EMC (Paris, France), Ophtalmologie ;
1998 : 29.
[76] SELLEM E., DENIS P.
Pharmacologie des médications antiglaucomateuses.
EMC (Elsevier, Paris), 1998 : 11.
[77] SHARPE ED., SIMMONS RJ.
Aragon laser trabeculoplasty as a means of decreasing intraocular
pressure from normal levels un glaucomatous eyes.
Am J Ophtalmol., 1985 ; 99 : 704-707.
[78] SHIELDS MB., RICH R., KRUPIN T.
Classification of the glaucomas.
2nd ed., Mosby eds ; 1996 : 1-4.
[79] STEINERT RF., THOMAS JV., BOGER WP.
Long term drift an continued efficacy after multiyear timolol
therapy.
Arch Ophthalmol., 1981 ; 99 : 100-103.
[80] STEWART RH., KIMBROUGH RL., WARD RL.
Betaxolol versus timolol : a 6-month double-blind comparison.
Arch Ophthalmol., 1986 ; 104 : 46-48.
[81] STEWART W.C.
Carteolol. An ophtalmic-adrenergic blocker with intrinsic
sympathomimetic activy.
J Glaucoma., 1994 ; 3 : 339-342.
[82] STEWART WC., RITCH R., SHIN DH., LEHMANN RP.
The efficacy of apraclonidine as an adjunct to timolol therapy.
Arch Ophthalmol., 1995 ; 113 : 287-292.
[83] STJEMSCHANTZ J.
Prostaglandins as ocular hypotensive agents, development of an
analogue for glaucoma treatment.
Adv Protaglandin Thromboxane Leukof Res, 1995 ; 23 : 63-68.
[84] STRAHLMAN E.R.; TIPPING R.; VOGEL R.
International Dorzolamide Study Group. A double-masked.
randomized one-year study comparing dorzolamide (Trusopt), timolol and
betaxolol.
Arch Ophthalmol., 1995 ; 113 : 1009-1016.
[85] THE BRIMONIDINE-ALT STUDY GROUP
Effect of brimonidine 0.5 % on intraocular pressure spikes
following 360 degree argon laser trabeculoplasty.
Ophthalmic Surg Lasers, 1995 ; 26 : 404-409.
[86] THOMPSON CD., McDONALD TL., GARST ME., WIESE
A.
Mechanisms of adrenergic agonist Induced allergy bioactivation
and antigen formation.
Exp Eye Res., 1997 ; 64 : 767-773.
[87] TOWNSEND DJ., BRUBAKER RF.
Immediate effect of epinephrine on aqueous formation in the
normal human eye as measured by fluorophotometry.
Invest Ophthalmol Vis Sci., 1980 ; 19 : 256-259.
[88] Zimmerman TJ.
Les collyres â-bloquants : une revue comparative.
J Ocul Pharmacol., 1993 ; 9 : 4-12.
| 
